Adropin to protect the brain after a subarachnoid hemorrhage
Official title: Neurovascular protection by adropin in acute neural injury from subarachnoid hemorrhage
Funded at University of Florida · NIH-11144279 · Data updated 2026-11-12
See whether a natural peptide called adropin can protect the brain and blood vessels in people who have had a subarachnoid hemorrhage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | August 15, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $375,018 |
| NIH project number | 5R01NS124620-04 |
| Project ID | NIH-11144279 on NIH RePORTER |
Who could benefit from this research
✓Could help
People who recently survived a subarachnoid hemorrhage and are at risk for delayed cerebral infarction would be the most relevant group for future related trials.
✕Less likely to help
People without subarachnoid hemorrhage or those with other types of brain injury are unlikely to receive direct benefit from this specific project.
What this research studies
Researchers are exploring whether boosting adropin can reduce brain cell damage and blood vessel problems that follow bleeding around the brain (subarachnoid hemorrhage). They will use laboratory models that mimic SAH to measure blood flow, vessel function, oxidative stress, and tissue injury while testing how adropin affects nitric oxide signaling and endothelial leakiness. The team may also analyze human samples or biomarkers to connect the lab findings to people who survive SAH. The aim is to point toward treatments that lower the risk of delayed brain infarction and long-term cognitive problems after SAH.
Why it matters
Potential benefit: If successful, this work could lead to new therapies that reduce brain injury and improve recovery after subarachnoid hemorrhage.
How similar studies have gone: Preclinical animal and cell studies show adropin influences eNOS activity and reduces endothelial damage, but clinical benefit in SAH patients has not yet been demonstrated.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Hoh, Brian Lim — University of Florida
- Study coordinator: Hoh, Brian Lim
Related research
Other NIH-funded projects on the same topics.
-
Cognitive screening after an aneurysmal brain bleed
Using patient questionnaires to find thinking and memory problems in people recovering from aneurysmal subarachnoid hemorrhage.
-
Blood test to predict delayed brain injury after an aneurysm bleed
This project is creating a blood test to spot which people who had a brain aneurysm bleed are likely to develop delayed brain injury in the days after the bleed.
-
3D brain blood vessel model to study subarachnoid hemorrhage and test therapies
A researcher will develop a 3D printed, biomimetic brain model to study subarachnoid hemorrhage and screen potential nanoparticle-based treatments.
-
Biomarkers to Fine-Tune Intrathecal Nicardipine for Brain Bleeding-Related Stroke
Researchers are testing biomarkers to personalize intrathecal nicardipine treatment for patients after subarachnoid hemorrhage to prevent brain damage.
-
Adropin as a shield for the brain after a brain hemorrhage
A potential treatment with adropin is being studied to protect brain cells after a subarachnoid hemorrhage and reduce stroke-like damage.
-
Manganese-based compound as a potential therapy for subarachnoid hemorrhage
A new manganese porphyrin-based drug is being explored as a possible treatment to reduce brain injury after a subarachnoid hemorrhage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.